Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A-30 Years of Experience in a Tertiary Care Center.


Journal

Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765

Informations de publication

Date de publication:
07 02 2022
Historique:
received: 30 12 2021
revised: 27 01 2022
accepted: 02 02 2022
entrez: 24 2 2022
pubmed: 25 2 2022
medline: 22 3 2022
Statut: epublish

Résumé

Aim of this study was to investigate the long-term results of botulinum toxin A (BoNT-A) injections for the treatment of benign essential blepharospasm (BEB) and to report our experience with (ultra-)long-term treatment with onabotulinumtoxin-A. We conducted a retrospective cross-sectional analysis at a university hospital. Patients with BEB and BoNT-A treatment were assigned to the Total Blepharospasm Group, patients with ≥21 onabotulinumtoxin-A injections to the Ona Long-Term Group. The Total Blepharospasm Group (

Identifiants

pubmed: 35202148
pii: toxins14020120
doi: 10.3390/toxins14020120
pmc: PMC8875585
pii:
doi:

Substances chimiques

Neuromuscular Agents 0
Botulinum Toxins, Type A EC 3.4.24.69

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Am J Ophthalmol. 1985 Feb 15;99(2):176-9
pubmed: 3970122
Eye (Lond). 2010 Apr;24(4):600-7
pubmed: 19648904
Arq Neuropsiquiatr. 2005 Jun;63(2A):221-4
pubmed: 16100966
Am J Ophthalmol. 2013 Jul;156(1):173-177.e2
pubmed: 23541393
J Neural Transm (Vienna). 2015 Mar;122(3):427-31
pubmed: 25059456
J Neurol. 2000 Oct;247(10):787-92
pubmed: 11127535
JAMA. 1982 Dec 17;248(23):3160-4
pubmed: 7143695
Neurotox Res. 2009 Apr;15(3):224-31
pubmed: 19384595
J Neurol Neurosurg Psychiatry. 1990 Aug;53(8):633-9
pubmed: 2213039
Mov Disord. 2002 Jan;17(1):7-12
pubmed: 11835433
Eur J Neurol. 2006 May;13(5):433-44
pubmed: 16722965
Clin Exp Ophthalmol. 2014 Apr;42(3):254-61
pubmed: 23844601
Medicine (Baltimore). 2021 Jun 25;100(25):e26481
pubmed: 34160460
Ger J Ophthalmol. 1995 Nov;4(6):363-7
pubmed: 8751102
Klin Monbl Augenheilkd. 1986 Oct;189(4):283-5
pubmed: 3807220
Arch Ophthalmol. 1985 Mar;103(3):347-50
pubmed: 3977705
Surv Ophthalmol. 2007 Jan-Feb;52(1):13-31
pubmed: 17212988
Neurology. 2016 May 10;86(19):1818-26
pubmed: 27164716
J Neural Transm (Vienna). 2011 Jun;118(6):925-43
pubmed: 21221669
Eur Neurol. 2015;73(5-6):337-41
pubmed: 25997849
Int Ophthalmol Clin. 2005 Summer;45(3):49-75
pubmed: 15970766
Eur J Ophthalmol. 2003 May;13(4):331-6
pubmed: 12872788
Toxins (Basel). 2013 Feb 04;5(2):249-66
pubmed: 23381141
Arq Neuropsiquiatr. 2012 Sep;70(9):662-6
pubmed: 22990720
Curr Opin Ophthalmol. 2018 Sep;29(5):440-444
pubmed: 29916840

Auteurs

Bettina Wabbels (B)

Department of Ophthalmology, University Hospital of Bonn, Ernst-Abbe-Street 2, D-53127 Bonn, Germany.

Rolf Fimmers (R)

Institute of Medical Biometry, Informatics and Epidemiology, University Hospital of Bonn, D-53127 Bonn, Germany.

Peter Roggenkämper (P)

Department of Ophthalmology, University Hospital of Bonn, Ernst-Abbe-Street 2, D-53127 Bonn, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH